Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/61760
IN VITRO AND IN VIVO EFFECTS OF P-MAPA IMMUNOMODULATOR ON SCHISTOSOMIASIS
Immunomodulators
P-MAPA
Praziquantel
Schistosoma mansoni
Schistosomiasis
Author
Affilliation
University of Pernambuco. Faculty of Medical Sciences. Recife, PE, Brazil.
Oswaldo Cruz Foundation. Aggeu Magalhães Institute. Recife, PE, Brazil.
Federal University of Pernambuco. Biosciences Centre. Department of Biochemistry. Recife, PE, Brazil.
Federal University of Pernambuco. Health Sciences Centre. Recife, PE, Brazil.
Farmabrasilis R&D Division. Valinhos, SP, Brazil.
University of Pernambuco. Faculty of Medical Sciences. Recife, PE, Brazil.
Oswaldo Cruz Foundation. Aggeu Magalhães Institute. Recife, PE, Brazil.
Federal University of Pernambuco. Biosciences Centre. Department of Biochemistry. Recife, PE, Brazil.
Federal University of Pernambuco. Health Sciences Centre. Recife, PE, Brazil.
Farmabrasilis R&D Division. Valinhos, SP, Brazil.
University of Pernambuco. Faculty of Medical Sciences. Recife, PE, Brazil.
Abstract
Schistosomiasis is an infectious disease caused by helminth parasites of the genus Schistosoma; it is transmitted in over 78 countries. The main strategy for schistosomiasis control is treatment of infected people with praziquantel (PZQ). As PZQ-resistant strains have emerged, new anti-schistosomal agents have become necessary. We evaluated the in vitro and in vivo effect of P-MAPA, an aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride with immunomodulatory properties; it is produced by Aspergillus oryzae fermentation. In vitro, P-MAPA (5, 50, and 100 µg/mL) damaged the Schistosoma mansoni tegument, causing thorn losses and tuber destruction in male worms and peeling and erosion in females after 24-h incubation. In vivo, P-MAPA (5 and 100 mg/kg, alone and combined with PZQ - 50 mg/kg) reduced the number of eggs by up to 69.20% in the liver and 88.08% in the intestine. Furthermore, granulomas were reduced up to 83.13%, and there was an increase in the number of dead eggs and a reduction of serum aspartate aminotransferase levels. These data suggest that P-MAPA activity can help improve schistosomiasis treatment and patients' quality of life.
Keywords
Antischistosomal agentsImmunomodulators
P-MAPA
Praziquantel
Schistosoma mansoni
Schistosomiasis
Share